Key Takeaways
- Vertex is halting development of VX-264, its islet cell treatment for type 1 diabetes, after it failed to show sufficient insulin production in trials.
- Data analysis indicated that increases in C-peptide, a key biomarker for insulin, were inadequate to warrant further clinical trials.
- Vertex continues to advance its other islet cell treatment, zimislecel, which is undergoing a phase 3 study and is set to complete dosing by mid-2025.
Vertex Discontinues VX-264 Development
Vertex Pharmaceuticals has announced the cessation of its clinical-stage islet cell treatment, VX-264, for type 1 diabetes, following disappointing results from a phase 1/2 trial. The therapy aimed to create insulin-producing cells that could be surgically implanted into patients with type 1 diabetes, but it did not trigger the necessary levels of insulin production.
In a recent market release, Vertex revealed that its 90-day data analysis found no significant increases in C-peptide levels, which are critical for indicating effective insulin production in response to food intake. While the treatment proved safe and well-tolerated among trial participants, the lack of improvement in C-peptide levels led Vertex to conclude that the therapy would not progress further in clinical studies.
Vertex plans to conduct additional analyses, including evaluations of the explanted devices used in the study, to gain deeper insights into these findings. Despite this setback, the company remains optimistic with another islet cell therapy, zimislecel, which is still in development. Zimislecel, derived from allogeneic human stem cells, is receiving attention as it is currently undergoing a phase 3 trial that is expected to complete dosing by the first half of 2025. This therapy includes the co-administration of immunosuppressants to facilitate cell grafting, distinguishing it from the earlier VX-264 approach.
Vertex’s Chief Medical Officer, Carmen Bozic, M.D., acknowledged the challenges faced with VX-264 but expressed enthusiasm for the progress of the zimislecel program. The company is actively working on enhancing its manufacturing and commercial capabilities to ensure readiness for a potential launch.
In light of the VX-264 development rollback, analysts at William Blair described the move as disappointing, particularly as VX-264 could have substantially diversified Vertex’s offerings in the type 1 diabetes market alongside zimislecel. They raised questions regarding the engraftment success of VX-264, especially regarding the encapsulation method and whether the absence of pharmaceutical immunosuppression had contributed to the treatment’s underwhelming efficacy.
Notably, Sana Biotechnology is advancing its own allogeneic cell therapy for type 1 diabetes, which holds promise after showing consistent levels of C-peptide in an individual patient during early testing. As the landscape for diabetes treatments evolves, Vertex’s commitment to exploring the challenges faced with VX-264 and the ongoing development of zimislecel will be closely monitored by stakeholders in the healthcare sector.
The content above is a summary. For more details, see the source article.